there was a trend toward better odds of an excellent functional outcome -- survival without disability at 90 days -- among patients who received a single periprocedural intra-arterial injection of ...

Stroke survivors were more likely to have little or no disability after 90 days if a clot was removed from a large brain ...

Removing a blood clot from a large brain artery, then injecting the clot-dissolving drug tenecteplase into the artery resulted in stroke survivors being more likely to have better function 90 days ...

Injecting tenecteplase into the artery after clot removal helps improve recovery in stroke survivors by enhancing blood flow ...

Intra-arterial injection. Premature infants. Risks from concomitant use with opioids; see Interactions. Monitor for respiratory depression and level of sedation; ensure availability of ...

RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, an innovative, FDA-cleared device, ...

For patients with acute ischemic stroke due to a large-vessel occlusion (LVO), administering intra-arterial thrombolytics after successful endovascular thrombectomy does not significantly improve ...

IV: 0.2mg given slowly over a period of no less than 60 seconds. Avoid intra-arterial, periarterial injection. Coronary artery disease or risk factors; may be more susceptible to developing MI and ...